C-XHURThymmune Therapeutics
iPSC-thymic cells, machine learning, cell therapy
replacementreplacingcell therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-XHUR
C-XHURC-XHURiPSC-thymic cells, machine learning, cell therapy
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Facebook Explore the things you love . Log into Facebook Email or mobile number Password Log in Forgot password? Create new account English (US) فارسی العربية Türkçe Deutsch Français (France) Polski More languages… Sign Up Log In Messenger Facebook Lite Video Meta Pay Meta Store Meta Quest Ray-Ban Meta Meta AI Instagram Threads Privacy Policy Privacy Center About Create ad Create Page Developers Careers Cookies Ad choices Terms Help Contact Uploading & Non-Users Meta © 2026
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Thymmune Therapeutics Receives $37M in Funding from the National… | Thymmune Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedI
Congratulations again to Stan Wang, MD, PhD, CEO of Thymmune Therapeutics and Boston Business Journal 40 Under 40 honoree! | Termeer Institute LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By click
[協同友社... - BTBA-Boston Taiwanese Biotechnology Association Facebook Log In BTBA-Boston Taiwanese Biotechnology Association's Post BTBA-Boston Taiwanese Biotechnology Association May 8, 2023 · Shared with Public [協同友社 BTPA-Boston Taiwanese Physicians Association 宣傳 Biomedical Entrepreneurship] Are you interested in entrepreneurship? Do you want to become the next founder of a biomedical technology company? BTPA is honored to invite Dr. Wang, CEO and Co-founder of Thymmune Therapeutics, to share with us how he embarked on the entrepreneurial path from the academic halls of Harvard Medical S
Thymmune Therapeutics raises funding to advance thymic cell therapies | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP-1 l
ARPA-H's First Industry Grant Sends $37M to Thymmune Therapeutics genprowebdirectory End Meta Pixel Code --> Facebook Linkedin RSS Twitter Youtube GEN Edge Featured News Multimedia Content News Insights Topics Artificial Intelligence Bioprocessing Cancer Drug Discovery Genome Editing Infectious Diseases OMICs Translational Medicine Magazine Browse Issues Subscribe Multimedia Summits Webinars GEN Live Learning Labs Podcasts Videos Resources A-Lists eBooks/Perspectives Tutorials Peer-Reviewed Journals GEN Biotechnology Re:Gen Open New Products Subscribe Get GEN Magazine Get GEN eNewsletters … e Get GEN eNewsletters Home Topics Drug Discovery ARPA-H’s First Industry Grant Sends $37M to Thymmune Therapeutics Cells body ARPA-H’s First Industry Grant Sends $37M to Thymmune Therapeutics October 2, 2023 Credit: Marcus Millo / 1137901057 / iStock / Getty Images Plus The Advanced Research Projects Agency for Health (ARPA-H), part of the U.S. Department of Health and Human Services, has announced up to $37 million to restore function to the thymus through fundi … deas for health research or technology breakthroughs. Continued support of each award is contingent on projects meeting aggressive milestones. The Open BAA began accepting abstracts in March 2023 and is open until March 2024. Future projects will be funded on a rolling basis. Industry News News Autoimmune diseases Health care organizations Machine learning T-cells Thymus Thymmune Therapeutics Share Facebook Twitter Linkedin ReddIt Email Also of Interest In vivo CAR-T and TCR- … in Autism Mouse Model Perseverance, Persistence Key to CAR T Success, Say Ross Prize Winners Carl June and Michel Sadelain Silica Nanoparticles Induce Ferroptosis, Reprogram Immunity in Prostate Cancer Models New mRNA Delivery Platform Restores Muscle Function in DMD Models Related Media AI in Protein Design: Hype vs. Reality Explained by David Baker Genetics in DC: A Report from ASHG Mechanistic Modeling Improves Drug Discovery Workflows and Speeds Therapeutic Development M
ARPA-H offers fast, flexible support to biotech startups, panelists tell… | Thymmune Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to
Thymmune Therapeutics | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance
Replacing your thymus | Thymmune Saturday Startup Stories Login Subscribe 0 Saturday Startup Stories Posts Replacing your thymus | Thymmune Replacing your thymus | Thymmune Episode 18 of S3 Jason Carman November 19, 2023 The first significant investment into the internet was done by ARPA in the 1960s. Today, ARPHA-H, a new government org focused on health R&D, just made its first ever investment into Thymmune, our featured startup for E18 of S³. Thymmune was founded in 2019 by Stan Wang, with the goal of developing novel therapies to treat a range of immune system disorders through scalabl … e transformative potential of these technologies, he saw a glaring gap in their application: they weren't being used to tackle one of the most critical aspects of our health – the aging immune system. Combining his deep scientific insights with a knack for entrepreneurship, Stan envisioned a company that could turn this groundbreaking science into a lifeline for millions. Thymmune isn't just a biotech company; it's the realization of Stan's belief that the best scientific inn
Thymmune Therapeutics and MLSC's Tax Incentive program | Massachusetts Life Sciences Center posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to … entive program helps fuel breakthrough science, innovation, and job growth. The deadline for the latest cycle of the Tax Incentive program is fast approaching. Learn more: https://lnkd.in/dxE4KJy …more 28 1 Comment Like Comment Share Copy LinkedIn Facebook X Chesley Chen 11mo Report this comment Nice, Stan Wang, MD, PhD and Kirk Taylor, MD ! Like Reply 1 Reaction To view or add a comment, sign in More Relevant Posts FUJIFILM Biosciences 28,836 followers 8mo Report this p … biomarker tests to deliver on the value of precision medicine. We are proud to award our 2025 Improving Diagnostics Education and Awareness (IDEA) Program grant to My Style Matters, Inc. and HYPE to Empower . Learn more: https://spkl.io/6045ApbP1 …more 73 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Los Angeles Biotech Networks 1,335 followers 8mo Report this post New Citruslabs Study Finds Droptics Eye Drops Help Refresh, Hydrade, and Energi
Fujifilm Biotechnologies transforms biomanufacturing with $8B investment and kojoX philosophy | FUJIFILM Biotechnologies posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn … Stan Wang, MD, PhD , CEO & Founder of Thymmune Therapeutics Learn more and apply to the Link to attend: https://lnkd.in/eEujUbij #CEOFounderLink 33 1 Comment Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Termeer Institute 7,546 followers 3mo Report this post The CEO & Founder Link's next gathering is on April 13 and will explore Building Great Companies by Building Great Leaders: Culture as Strategy. As biotech companies scale, success … d: Stan Wang, MD, PhD , CEO & Founder, Thymmune Therapeutics Learn more and apply to attend: https://lnkd.in/eEujUbij #CEOFounderLink MassBio 48,914 followers 3mo Exclusively for life sciences CEOs and founders, MassBio and the Termeer Institute bring leaders together through the CEO & Founder Link. Our next event on April 13 explores Building Great Companies by Building Great Leaders: Culture as Strategy. As biotech companies scale, success requires more than groundb … Stan Wang, MD, PhD , CEO & Founder of Thymmune Therapeutics Learn more and apply to the Link to attend: https://lnkd.in/eEujUbij #CEOFounderLink 30 Like Comment Share Copy LinkedIn Facebook X To view or add a comment, sign in Virdis Group 3,170 followers 3mo Edited Report this post Virdis Group at BIO-Europe Spring & LSX World Congress The coming weeks will bring together leaders from across the global life sciences ecosystem, and Virdis Group is pleased to be attend … ke this system resilient over time?” This is where biomimicry moves from idea → application. Not as a layer on top. But as a lens that reshapes the question itself. At Biomimicry Switzerland, we are interested in working with organizations willing to test this in practice. Not perfectly. But seriously. If you are exploring: • new product developm
#hiring | Thymmune Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . … arch Associate/ Senior Research Associate, In Vivo in Cambridge, Massachusetts. Apply today or share this post with your network. Research Associate/ Senior Research Associate, In Vivo Thymmune Therapeutics, Cambridge, MA 35 2 Comments Like Comment Share Copy LinkedIn Facebook X Amalia Eduany Ramirez Silva 1w Report this comment CFBR Like Reply 1 Reaction Darren Nelson 1w Report this comment Every breakthrough therapy starts as a hypothesis. The people who turn that hypo
RePORT ⟩ RePORTER We're sorry but RePORTER doesn't work properly without JavaScript enabled. Please enable it to continue.
Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies - Pharmaceutical Technology Skip to site menu Skip to page content Switch language: .translate --> PT Menu Search Sections Home News Analysis Features Comment & Opinion Projects Data Insights Pharma Clinical Trials Drug Manufacturers Therapy Area Cardiovascular Central Nervous System Immunology Infectious Disease Oncology Respiratory Pricing and Market Access Themes Artificial Intelligence Corporate Governance Cloud Cybersecurity Environmental Sustainability Internet of Things Robotics Social Responsibility Covid-19 Insig … t 2027 Buy Reports Newsletters PT News Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies Thymmune Therapeutics is undertaking the eponymous Thymus Rejuvenation project, which aims to restore damaged or non-functional thymus tissue. Robert Barrie September 29, 2023 Share Copy Link Share on X Share on Linkedin Share on Facebook The Massachusetts-based biotech says this would demonstrate a clinical pathway to treat patients who lack a functional thymus. Im … h engaged professionals across 36 leading media platforms. Find out more By DSO Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+880) Barbados (+1246) Belarus (+375) Belgium (+32) Belize (+501) Benin (+229) Bermuda (+1441) Bhutan (+975) Bolivia (+591) Bosnia Her … olicy Tick here to opt out of curated industry news, reports, and event updates Submit Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email addr … ve an email shortly. Please check your inbox to download the Whitepaper. By DSO Submit Country Code * UK (+44) USA (+1) Algeria (+213) Andorra (+376) Angola (+244) Anguilla (+1264) Antigua & Barbuda (+1268) Argentina (+54) Armenia (+374) Aruba (+297) Australia (+61) Austria (+43) Azerbaijan (+994) Bahamas (+1242) Bahrain (+973) Bangladesh (+8
Thymmune Therapeutics – Vaia – Talents Your Career Hub Vaia Job Board Find your dream job on the largest job board for Gen-Z worldwide. Find a job Featured Companies In the spotlight All Jobs Over 2 million jobs are waiting for you. Featured Companies Top companies we pre-selected for you. Vaia App Discover our mobile app to take your studies anywhere. Vaia Blog https://www.vaia.com/en-us/magazine/ Start Applying Start Applying Vaia Job Board Find a job Featured Companies Thymmune Therapeutics Jobs Details Number of employees 50-100 About Thymmune Therapeutics Thymmune Therapeutics
Thymmune - Comm Ink Services Website Design Branding Graphic Design Brand Strategy Capital Campaigns Copywriting Digital Marketing Promotional Products Event Marketing Video & Photography Signage Work About Blog Contact Branding & Logo Design Promotional Products Thymmune: Restoring immune function through thymic cell engineering Developing Scalable Therapies for Aging and Disease. Client Thymmune Therapeutics Services Branding Promotional Products We were approached by this startup life science company to help them create a new logo. The company is focused on delivering therapies tha
Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu Restoring Immune Function through Thymic Cell Engineering Developing Scalable Therapies for Aging and Disease Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company’s cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune disord … s to develop thymus-rejuvenating therapies. READ MORE BBJ: Thymmune gets ARPA-H grant to boost immune function in aging people READ MORE Thymmune Secures $7M in Seed Financing Thymmune secures $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors. READ MORE Endpoints: Thymmune launches with backing from George Church, John Maraganore The Cambridge, MA-based biotech has raised $7 million in seed funding to push its thymic cell … MORE 2021 Thymmune Wins Astellas Golden Ticket Böhringer Ingelheim’s Innovation Prize LG Chem Life Sciences Golden Ticket Novo Nordisk Golden Ticket Pfizer Golden Ticket Winner Join us At Thymmune, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated diseases. We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the … ch team member at Thymmune. To be considered for a position at Thymmune, please submit your CV and cover letter. Recruitment & Staffing Agencies: Thymmune Therapeutics does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Thymmune or its employees is strictly prohibited unless contacted directly by Thymmune’s internal Talent Acquisition team. Any resume submitted by an agency … une, and Thymmune will not owe any referral or other fees with respect thereto. SUBMIT View fullsize 215 First Street, Suite 401 Cambridge, MA 02142
Pillar VC Portfolio Companies | Science and Tech Founders Skip to content Our Approach Our Focus Our Belief Founder Resources Common Stock Companies Team Founder Resources Founder Playlist Founder Resources Encode Pillar Events Our Approach Our Focus Our Belief Founder Resources Common Stock Companies Team Founder Resources Founder Playlist Founder Resources Encode Pillar Events X (Twitter) Linkedin Thymmune is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. thymmune.com Stan Wang Founder & … , 9th Floor, Boston, MA 02116 X (Twitter) Linkedin Announcing Pillar VC's $175M Fund IV
Research Associate/Senior Research Associate, In Vivo Pharmacology - Thymmune Therapeutics - Career Page Skip To Job Description View All Jobs View Our Website Thymmune Therapeutics Thanks for visiting our Career Page. Please review our open positions and apply to the positions that match your qualifications. Research Associate/Senior Research Associate, In Vivo Pharmacology Cambridge, MA Full Time R&D Mid Level Share About Us Thymmune Therapeutics is a preclinical biotechnology company based in Cambridge, MA applying proprietary insights in thymic engineering to develop and commercialize … uorescence imaging. Identify and validate target markers for cell profiling and apply these markers to correlate in vitro characteristics with in vivo outcomes. Maintain cell culture of cell line or primary immune cells using aseptic techniques. Develop and execute immunological assays (e.g., cell activation, cytotoxicity, mixed lymphocyte reaction) to assess the allo-reactivity and tolerance of immune cells. Data Analysis, Reporting, & Collaboration Document in vitro and … ties, and work effectively in a collaborative, team-oriented environment. Share Apply Apply for this position Required * First Name * Last Name * Email Address * Phone * Address Resume * We've received your resume. Click here to update it. Attach resume or Paste resume Attach resume as .pdf, .doc, .docx, .odt, .txt, or .rtf (limit 5MB) or Paste resume Paste your resume here or Attach resume file Are you legally authorized to work in the United States? * -- No answer -- Yes No … proficient in aseptic cell culture techniques? Please describe. * Human Check * Submit Application This website uses cookies and other analytics technologies. By selecting "Allow", you consent to the recording, use and sharing of your website activity by this website and its service providers. Allow Reject All Powered by
Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal — Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal press Mar 1 Written By Stan Wang March 01, 2023 Cambridge, MA – Thymmune Therapeutics , a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, announced today that it has secured $7 million in seed financing led by Pillar VC, with participa
US government backs thymus rejuvenation project with $37m Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs team up to ... Xell
Dave's Research Corner - March 2023 - Spotlight on Thymmune - APS Type 1 Foundation, Inc. Skip to content APS Type 1 Foundation, Inc. Facebook Instagram Donate Home About Our Mission Our Impact Foundation Leadership Medical Advisory Committee Financial Reports Contact Us Education What is APS Type 1? Newly Diagnosed? Family Resources Symposium 2023 Symposium 2021 Symposium 2019 Symposium 2017 Symposium 2015 Symposium Clinician Information Resources Research Foundation-Funded Research NIH Natural History Study NIH Clinical Trial: Alopecia Areata in APECED NIH Clinical Trial: APECED Enterit
This stem cell startup is designing a therapy to restore and boost immunity - The Boston Globe Skip to main content Sections Epaper Sports Red Sox Patriots Celtics Bruins High Schools Colleges Women's Sports TV & Radio Metro Weather Politics Transportation Education Cambridge & Somerville Around Mass. Investigations Obituaries Death Notices Games & Puzzles Align Crossword Mini Crossword KenKen Sudoku Word Flower Business Technology Economy Housing Real Estate Biotech The Fine Print Bold Types Politics Money, Power, Inequality Climate Spotlight Opinion Ideas Columns and Op-eds
Immune System Rejuvenation : P…–Modern Healthspan – Apple Podcasts Search Home New Top Charts Search October 22, 2023 13 min Immune System Rejuvenation : Path To The Clinic | Dr Stan Wang Ep2 Modern Healthspan Play In this video Dr Wang talks about the current state of trials and how the therapy might eventually look. Stan Wang is Founder and CEO of Thymmune Therapeutics, a cell therapy company working to address high unmet needs across immunology. Previously, Stan was Founding Chief Scientific Officer at Cellino Biotech, where he led R&D and application of its technology to rapidly engine
In Vivo Immunology Research Associate, iPSC Thymic in Cambridge at Thymmune Therapeutics | Apply now! – StudySmarter – Talents Everything for your career Find a job In Vivo Immunology Research Associate, iPSC Thymic in Cambridge Apply Now Apply Now Job Board Companies Thymmune Therapeutics In Vivo Immunology Research Associate, iPSC Thymic In Vivo Immunology Research Associate, iPSC Thymic in Cambridge Cambridge Full-Time 65000 - 85000 $ / year (est.) No home office possible Apply Now Apply Now T At a Glance Tasks: Conduct exciting research on innovative cell therapies using mouse models. Comp … haring your experiences on platforms like ResearchGate to enhance visibility. ✨ Apply Directly On Company Websites When you find a company you're excited about, like Thymmune Therapeutics, go directly to their careers page and apply. Many biotech firms prefer to source candidates from their own sites. Also, it shows initiative and that you’re serious about joining the team! We think you need these skills to ace In Vivo Immunology Research Associate, iPSC Thymic in Cambrid … Abilities Complex Study Design Mentoring Industry Experience Some tips for your application 🫡 Showcase Your Scientific Skills: When applying for a full-time role in biotechnology, it's crucial to highlight your relevant scientific skills and experience. Include specific techniques or technologies you've worked with, like CRISPR or mass spectrometry, in your CV. This way, we can see that you have the hands-on experience necessary for the position at Thymmune Therapeut … ring cross-functional team initiatives. This can make a huge difference in your application quality. How to prepare for a job interview at Thymmune Therapeutics ✨ Showcase Your Technical Know-How In biotechnology, it's crucial to demonstrate a strong grasp of relevant techniques and tools—so be prepared to discuss the lab methods you've used or any specific projects you’ve been part of. Bring along any data or results that highlight your contributions; we want to see … y data or results that highlight your contributions; we want to see how you can apply science to real-world problems! ✨ Brush Up on Your Problem-Solving Skills Biotech interviews often include hypothetical scenarios where you might have to troubleshoot a research problem. Practice articulating your thought process as you navigate these challenges
Thymmune Therapeutics - Career Page Skip To Job Description View All Jobs View Our Website Thymmune Therapeutics Thanks for visiting our Career Page. Please review our open positions and apply to the positions that match your qualifications. Current Openings Research Associate/Senior Research Associate, In Vivo Pharmacology Cambridge, MA R&D This website uses cookies and other analytics technologies. By selecting "Allow", you consent to the recording, use and sharing of your website activity by this website and its service providers. Allow Reject All Powered by
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Thymmune - 2026 Company Profile, Team, Funding & Competitors - Tracxn JavaScript is disabled in your browser. enable it to enjoy the full features of Tracxn. Your browser was unable to load all of Tracxn resources. They may have been blocked by your firewall, proxy or browser configuration. Press Ctrl+F5 or Ctrl+Shift+R to have your browser try again and if that doesn't work, click here to retry or mail us at [email protected] Internal Server Error Toggle navigation Customers Investment Industry Venture Capital Funds Private Equity Funds Accelerators & Incubators Investment Banks Corp … ge, United States Stage Seed Total Funding $7M in 4 rounds Latest Funding Round Grant (prize money), Apr 28, 2025 , $***** Investors Pillar VC & 7 more Ranked 111 th among 390 active competitors Employee Count 27 as on May 31, 2026 Similar Companies Kronos Bio & 429 more View Thymmune's full profile Sign up to download Thymmune's company profile Sign Up for Free Thymmune's funding and investors Thymmune has raised a total funding of $7M over 4 round s . … . Its first funding round was on Apr 15, 2022 . Its latest funding round was a Grant (prize money) round on Apr 28, 2025 for $ ***** . 1 investor participated in its latest round. Thymmune has 3 institutional investor s and 5 angel investor s . Here is the list of recent funding rounds of Thymmune : Filter this list Date of Funding Funding Amount Round Name Post-Money Valuation Revenue Multiple Lead Investors Other Investors Apr 28, 2025 3721327 Grant (prize money) 4686613 2 … 721327 Grant (prize money) 4686613 2964523 5457501 6759455 Jan 19, 2025 7699921 Grant (prize money) 6244375 2772043 9432888 HHS Mar 01, 2023 5610830 Seed 8886326 8411171 Pillar VC Mark Bamforth & 5 more Access funding benchmarks and valuations. Sign up today! View details of Thymmune 's funding rounds and investors Thymmune's founders and board of directors Founder? Claim Profile The founders of Thymmune is Stan Wang . Stan Wang is the CEO of Thymmune . Here are … to Thymmune News related to Thymmune • Cambridge biotech Thymmune wins $37m NIH grant for thymic cell therapies Pharmaceutical Technology • Sep 29, 2023 • Thymmune , HHS , Arpa H • George Church-Backed Thymmune Launches to Target Overlooked Organ BioSpace • Mar 02, 2023 • Thymmune • Thymmune Raises $7M in Seed Financing FinSMEs • Mar 01, 2023 • T
Stem Cell Program 20th Anniversary Symposium Stem Cell Program 20th Anniversary Symposium Hosted by Boston Children's Hospital Tuesday, April 15, 2025 8:30 a.m. to 5:15 p.m. Folkman Auditorium 320 Longwood Ave. Boston, MA 02115 The Boston Children’s Hospital Stem Cell Program’s 20th Anniversary Symposium will explore the basic science of, and clinical progress in, stem cell biology and cell-based therapies. This in-person event will foster active exchange among speakers and attendees from the Boston community. Speakers will include preeminent stem cell scientists from academia and bioph
Thymmune Therapeutics Company Profile: Financials, Valuation, and Growth | PrivCo Sign In Create Free Account PrivCo Thymmune Therapeutics Thymmune Therapeutics Cambridge, MA Watchlist Export About Financials People Deals Funding About Thymmune Therapeutics Company overview Thymmune Therapeutics is a privately-held biotechnology company that develops and commercializes immune cell therapy products. Thymmune Therapeutics was founded in 2019 by Stan Wang. Thymmune Therapeutics headquarters are located in Cambridge, Massachusetts. Keywords Revenue Revenue EBITDA EBITDA Valuation Valuation Income
Thymmune Therapeutics - 6th iPSC Drug Development Summit Skip to content Free to Attend for Biopharma & Academics* September 9-10, 2026 | Boston, MA About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last 12 Months: Why This Year Matters More Than Most Hanson Wade Products What’s On? Full Event Guide Speakers Agenda Day One Day Two Why Partner Why Partner Partners Media Partners Take Part Pricing & Registration Venue & Accommodation Contact Us Event Guide Register About About the Summit FAQs Poster Session Content Hub iPSC Development in the Last
Home - original — Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu Restoring Immune Function through Thymic Cell Engineering Developing Scalable Therapies for Aging and Disease Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company’s cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-relate … s to develop thymus-rejuvenating therapies. READ MORE BBJ: Thymmune gets ARPA-H grant to boost immune function in aging people READ MORE Thymmune Secures $7M in Seed Financing Thymmune secures $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors. READ MORE Endpoints: Thymmune launches with backing from George Church, John Maraganore The Cambridge, MA-based biotech has raised $7 million in seed funding to push its thymic cell … MORE 2021 Thymmune Wins Astellas Golden Ticket Böhringer Ingelheim’s Innovation Prize LG Chem Life Sciences Golden Ticket Novo Nordisk Golden Ticket Pfizer Golden Ticket Winner Join us At Thymmune, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated diseases. We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the … ch team member at Thymmune. To be considered for a position at Thymmune, please submit your CV and cover letter. Recruitment & Staffing Agencies: Thymmune Therapeutics does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Thymmune or its employees is strictly prohibited unless contacted directly by Thymmune’s internal Talent Acquisition team. Any resume submitted by an agency … une, and Thymmune will not owe any referral or other fees with respect thereto. SUBMIT View fullsize 215 First Street, Suite 401 Cambridge, MA 02142
LG Chem Life Sciences Innovation Center and LabCentral Announce the 2021 Golden Ticket Winner – Thymmune Therapeutics, Inc. - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Busin … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown LG Chem Life Sciences Innovation Center and LabCentral Announce the 2021 Golden Ticket Winner – Thymmune Therapeutics, Inc. August 23, 2021 | 3 min read Twitter LinkedIn Facebook Email Print Today, LG Chem Life Sciences Innovation Center announces that it has selected Thymmune Therapeutics as the winner of thei … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health's Advanced Research Projects Agency for Health (ARPA-H) - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Ma … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Policy Thymmune Therapeutics Receives $37M in Funding from the National Institutes of Health’s Advanced Research Projects Agency for Health (ARPA-H) September 29, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Thymmune Therapeutics announced that the U.S. Department of Health and Human Servic … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search Genetown Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal March 1, 2023 | 3 min read Twitter LinkedIn Facebook Email Print Thymmune Therapeutics, a biotechnology company developing scalable thymic cell therapies to restore immune function in aging and disease, anno … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
George Church-Backed Thymmune Launches to Target Overlooked Organ - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business George Church-Backed Thymmune Launches to Target Overlooked Organ March 2, 2023 | 2 min read | Tristan Manalac Twitter LinkedIn Facebook Email Print Stan Wang, M.D., Ph.D., founder and CEO, Thymmune Thymmune is backed by an A-list team of investors including Pillar VC, former Aln … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Boston Globe: Mass. Lawmakers Seek Answers on Apparent Effort to Wind Down ARPA-H Investor Catalyst Hub in Cambridge - MassBio Skip to content MassBio Massachusetts Biotechnology Council Primary Menu Search for: Search Open search form Sign In Become a Member MB Vision Search for: Search Members Become a Member Types & Rates Benefits Savings and Rewards Member News Member Events Career Center Directory Pay Company Dues FAQs Events Upcoming Types of Events Sponsorship Opportunities Massachusetts: The State of Possible Align Summit Member Events Innovation About Drive Application Alumni Par … eived up to $37 million for its thymus rejuvenation project, the first industry award through ARPA-H’s Open BAA. Mass General Brigham has also been awarded multiple ARPA-H contracts to deliver hospital-level care to rural communities. The hub structure makes strategic sense. Congress directed ARPA-H to operate in at least three geographic areas. Placing the Investor Catalyst Hub in the world’s leading life sciences ecosystem, alongside the Customer Experience Hub in Dal
Research Associate/Senior Research Associate, In Vivo Pharmacology @ Thymmune Therapeutics | Jobright.ai SIGN IN JOIN NOW Research Associate/Senior Research Associate, In Vivo Pharmacology jobs in United States Overview Company This job has closed. APPLY to similar jobs Thymmune Therapeutics · 4 months ago Research Associate/Senior Research Associate, In Vivo Pharmacology Cambridge, MA Full-time Onsite Entry, Mid, Senior Level 1+ years exp Thymmune Therapeutics is a preclinical biotechnology company based in Cambridge, MA focused on developing immune cell therapy products. They are seeking a h … luorescence imaging Identify and validate target markers for cell profiling and apply these markers to correlate in vitro characteristics with in vivo outcomes Maintain cell culture of cell line or primary immune cells using aseptic techniques Develop and execute immunological assays (e.g., cell activation, cytotoxicity, mixed lymphocyte reaction) to assess the allo-reactivity and tolerance of immune cells Document in vitro and in vivo studies using electronic notebook (e.g., … Key Investors Advanced Research Projects Agency for Health Pillar VC 2023-09-29 Grant· $37M 2023-03-01 Seed· $7M Leadership Team Stan Wang CEO & Founder Bing Lim Chief Scientific Officer Recent News Google Patent COMPOSITIONS OF THYMIC CELLS AND METHODS OF USE THEREOF 2025-05-04 Google Patent Thymic cell compositions and methods of making 2025-02-09 Google Patent Thymic cells and methods of making 2025-02-09 Company data provided by crunchbase Boost Your Interview Chances … onse via Email Outreach L Linda L. Technical Recruiter Draft Message to Connect Apply Faster with Autofill Plugin FREE Apply With Autofill
‘We want to give everyone a new thymus to reboot their immune system’ Skip to content News Data Podcast Clinics News Data Podcast Clinics Search Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Advertise NEWSLETTER News Data Podcast Clinics News Data Podcast Clinics Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire Investment Biotech Research AI/Tech Supplements Clinics Ecosystem LT Wire About Contact About Contact Advertise nEWSLETTER Search Search DiamiR, AlzLabs team up … ghlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency You might also like Scribe lands $25m to advance heart disease gene therapies ŌURA-LillyDirect collab highlights new GLP-1 care model GARM Clinic debuts world’s first Klotho longevity residency NorthStrive eyes emerging GLP-1 opportunity: muscle preservation Stem cell banking partnership targets future of longevity Danny Sullivan Danny has worked in technology communications for more tha
CDTR: Stem Cell-Derived Thymus Rejuvenation | ARPA-H Skip to main content An official website of the United States government Here's how you know The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site. The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. About About Us Our People Partnering with ARPA-H Budget & Appropriations FAQs Contact Explore Funding Open Funding … urces and FAQs Program Portfolio Initiatives & Sprints For Small Businesses Award Directory Engage & Connect Commercialization Services ARPA-H Network International Affairs Other Transaction Community News & Events News Events Posters Careers Career Opportunities What is a Program Manager? Program Manager Application Search Breadcrumb Home / Explore Funding / Awards / CDTR: Stem Cell-Derived Thymus Rejuvenation CDTR: Stem Cell-Derived Thymus Rejuvenation Thymmune … es a crucial unmet need to rejuvenate immunity in the aging population. Back to Award Directory Mission Office Award Health Science Futures Project Award Details Award Start Date September 25, 2023 Award Amount Up to $37M Prime Awardee Thymmune Therapeutics Principal Investigator(s) Bing Lim, M.D., Ph.D. and Stan Wang, M.D., Ph.D. Location Cambridge, MA Managing Office Health Science Futures Office Vitals Newsletter Stay Connected Keep a pulse on new funding opportunities, re … urces and FAQs Program Portfolio Initiatives & Sprints For Small Businesses Award Directory Engage & Connect Engage & Connect Commercialization Services ARPA-H Network International Affairs Other Transaction Community News & Events News & Events News Events Posters Careers Careers Career Opportunities What is a Program Manager? Program Manager Application Policies & Information Policies & Information Accessibility Privacy Policy Freedom of Informat
Thymmune Therapeutics | Eva Garland Consulting About Us Our Professionals Services Funding Your Science Accounting & Compliance Our Impact Resources Contact Us Search Thymmune Therapeutics In BioPharm $58M ARPA-H Award Advanc es Next-Gen eration Thymic Cell Therapies Client: Thymmune Therapeutics Location: Cambridge, Massachusetts Founded: 2019 Sector: BioTech Link: https://www.thymmune.com/ $ 38 M Non-dilutive funding awarded The human immune system declines with age and can be severely compromised by disease or medical treatments, leaving millions of patients vulnerable and with limited … restoration. “The [EGC] consultants all had significant experience with grant writing and had been able to guide us quickly into the format and other documentary requirements unique to each Grant proposal. Scientific knowledge of the consultants was also excellent enabling significant feedback and contribution to the proposal.” – Bing Lim, MD, Ph.D , CSO of Thymmune Therapeutics For almost five years, EGC has been proud to support Thymmune through grant writing assist … eering. During this time, Thymmune has secured over $58 million in non-dilutive grant funding. We are excited to witness their ongoing growth and impactful contributions! $ 58 M Non-dilutive funding awarded + 5 Years as EGC client Funding Sources Accelerating development of innovative technologies EGC’s extraordinary team of scientists and accountants are ready to secure and manage non-dilutive funding to support your scientific innovations. Contact us to learn more. Book a D
ARPA-H funding to support Thymmune Therapeutics’ Thymus Rejuvenation project | Kimberly Ha LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … Report this post Thanks Bioworld for covering Thymmune Therapeutics recent $37m grant funding. The U.S. Department of Health and Human Services, through the Advanced Research Projects Agency for Health (ARPA-H), has awarded up to $37 million in funding to the Thymus Rejuvenation project, led by Thymmune Therapeutics Inc. https://lnkd.in/e-XMiwby Stan Wang, MD, PhD Pillar VC Thomas de Vlaam NYBC Ventures Meg Wood Advanced Research Projects Agency for Health (ARPA-H) ARPA-H fun
Thymmune Therapeutics, Inc. Asset Profile | Preqin Skip to main content Products Our products Preqin Pro Alternative assets data platform Private Markets Research Industry research Term Intelligence Benchmark LPA terms Preqin Benchmarks Industry's leading performance data Preqin Sustainability ESG data and insights Company Intelligence Companies & deals data Enterprise Data Solutions Flexible data delivery solutions Transaction Intelligence A $5.4tn transaction repository Client stories What our clients say Quick Links Our data Asset classes we cover Create a free account Newsletter C … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Quick Links Our data Asset classes we cover Create a free account Newsletter Contribute data Contact us Insights+ Private markets research Homepage Browse reports Search Search the research library Webinar recordings Join conversations with our analysts Meet the analysts Meet the team behind the reports Learn more Learn more about Private Markets Resear … r analysis Keep up with market trends Spot new business opportunities Benchmark fund terms Navigate private credit investing Insights+ Homepage Search Webinar recordings Meet the analysts Learn more News & content Homepage Events Free Benchmarks Data coverage map Preqin Profiles Preqin Academy Compensation calculator About Who we are Our corporate responsibility Partners Press hub Careers Contact us QuickLinks Our data Asset classes we cover Create a free account Newslett … ed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers. Request demo Thymmune Therapeutics, Inc. - overview Established 2019 Location Cambridge, MA, US Primary Industry Biotechnology About Based in Massachusetts, US, and founded in 2019 by CEO Stan Wang, Thymmune Therapeutics, Inc. , a. k. a. Thymmune Therapeutics is a biotechnology company that is developing scalable thera … go Pro Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more. Sign in Request demo Our Company Who We Are Our Corporate Responsibility Partners
Stan Wang Stan Wang, md, phd CEO & Founder, Thymmune Therapeutics Summary Media Experience Skills Education Get in touch Contact form Summary Stan Wang, MD, PhD , is CEO & Founder of Thymmune Therapeutics, a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale for a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune disorders. Previously, he was F … 2011 - May 2015 Supervised by Roger Pedersen & Sir John Gurdon (2012 Nobel Prize in Physiology or Medicine) National Institutes of Health Pre-doctoral IRTA Fellow August 2011 - June 2015 Supervised by Vittorio Sartorelli Skills & Expertise Biotechnology Stem Cells Regenerative Medicine Genome Engineering Entrepreneurship People Skills Education Columbia University College of Physicians and Surgeons M.D. 2016 NIH T32-funded Medical Scientist Training Program Universit … ker at Commencement Let's Connect LinkedIn Boston Contact me Name Email Message Submit Comment Cookie Use We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies. Accept Learn More
Thymmune Therapeutics Announces Manish Jain as CTO — Thymmune Therapeutics | Thymmune Therapeutics LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree t
press — Press — Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu press Stan Wang 7/24/24 press Stan Wang 7/24/24 Thymmune Therapeutics Announces Manish Jain as CTO Read More press Stan Wang 3/1/23 press Stan Wang 3/1/23 Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal Read More View fullsize 215 First Street, Suite 401 Cambridge, MA 02142
Manish Jain - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Win Deals Through Your Network Transform relationships with clients, colleagues, and partners into actionable insights. Search for an Executive Trusted by Trusted by Featured Profile Manish Jain CHIEF TECHNOLOGY OFFICER at Thymmune Therapeutics Manish Jain 's Executive Work History Current CHIEF TECHNOLOGY OFFICER , CHIEF TECHNOLOGY OFFICER Equilar on 07/25/2025 Thymmune Therapeutics Past To view Manish Jain's complete executive work history, sign up now Manish Jain 's Connections (6) Pamela Lapham Vice
Press — Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu press Stan Wang 7/24/24 press Stan Wang 7/24/24 Thymmune Therapeutics Announces Manish Jain as CTO Read More press Stan Wang 3/1/23 press Stan Wang 3/1/23 Thymmune Secures $7M in Seed Financing to Develop Thymus Cell Therapy Platform for Immune System Renewal Read More View fullsize 215 First Street, Suite 401 Cambridge, MA 02142
Thymmune Therapeutics Announces Manish Jain as CTO — Thymmune Therapeutics | Manish Jain | 47 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agr
Thymmune Therapeutics Announces Manish Jain as CTO — Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu Thymmune Therapeutics Announces Manish Jain as CTO press Jul 24 Written By Stan Wang Biotech company developing thymic cell engineering platform bolsters leadership team with veteran biopharmaceutical hire July 24, 2024 Cambridge, MA – Thymmune Therapeutics , a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease, today announced that Manish Jain has joined the c
Thymmune Therapeutics Inc | www.inknowvation.com --> --> --> --> --> --> --> > https://gasparesganga.com/labs/jquery-loading-overlay/#examples --> > https://gasparesganga.com/labs/jquery-loading-overlay/#examples --> Skip to main content idi Toggle navigation 0 You have 0 notifications Site Visitor Site Visitor New To Inknowvation.com? Register now to get an access to proprietary SBIR-STTR databases! Registration is fast and free - start your access to business-actionable information today! Login Site Register Home My Work Area About My Work Area SBIR Community About SBIR Community SBIR Awarde … estoring immunefunction through thymic cell engineering Year Founded 2019 First Award 2022 Latest Award 2024 Program Status Active : At least one SBIR-STTR award (Phase I or Phase II) in last five years Inactive : Last award dollars more than FIVE years ago"> Program Status Active Popularity Index The Popularity Index is a rank (scale 1-100) assigned to each SBIR company, based on the number of hits to the company record. Currently Most Popular - click the name to see - … password. Please enter email address that is associated with your account. Back Submit ' type='hidden'> Still Need Help? If you need further assistance, send us an e-mail and we will assist you in resetting your account. Forgot password? Mail sent successfully. Enter username and password. Please enter email address that is associated with your account. Back Submit ' type='hidden'> Still Need Help? If you need further assistance, send us an e-mail and we will assist you in re
EP4359566A4 - THYMUS CELL COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents EP4359566A4 - THYMUS CELL COMPOSITIONS AND METHODS OF USE THEREOF - Google Patents THYMUS CELL COMPOSITIONS AND METHODS OF USE THEREOF Info Publication number EP4359566A4 EP4359566A4 EP22829251.2A EP22829251A EP4359566A4 EP 4359566 A4 EP4359566 A4 EP 4359566A4 EP 22829251 A EP22829251 A EP 22829251A EP 4359566 A4 EP4359566 A4 EP 4359566A4 Authority EP European Patent Office Prior art keywords methods cell compositions thymus cell thymus compositions Prior art date 2021-06-23 Legal status (The legal status is an … s and makes no representation as to the accuracy of the status listed.) Pending Application number EP22829251.2A Other languages German ( de ) French ( fr ) Other versions EP4359566A1 ( en Inventor Bing Lim Da Rocha Edroaldo Lummertz Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Thymmune Therapeutics Inc Original Assignee Thymmune Therapeutics Inc Pri … sted.) 2021-06-23 Filing date 2022-06-22 Publication date 2025-08-06 2022-06-22 Application filed by Thymmune Therapeutics Inc filed Critical Thymmune Therapeutics Inc 2024-05-01 Publication of EP4359566A1 publication Critical patent/EP4359566A1/en 2025-08-06 Publication of EP4359566A4 publication Critical patent/EP4359566A4/en Status Pending legal-status Critical Current Links Espacenet EPO GPI EP Register Global Dossier Discuss Classifications C — CHEMISTRY; METALLURG … DS OF USE THEREOF Pending EP4359566A4 ( en ) Applications Claiming Priority (5) Application Number Priority Date Filing Date Title US202163214176P 2021-06-23 2021-06-23 US202163256445P 2021-10-15 2021-10-15 US202263296250P 2022-01-04 2022-01-04 US202263321142P 2022-03-18 2022-03-18 PCT/US2022/034579 WO2022271862A1 ( en ) 2021-06-23 2022-06-22 Thymic cell compositions and methods of use thereof Publications (2) Publication Number Publication Date EP4359566A1 EP4359566A1 ( en ) … 4 true EP4359566A4 ( en ) 2025-08-06 Family ID=84544797 Family Applications (1) Application Number Title Priority Date Filing Date EP22829251.2A Pending EP4359566A4 ( en ) 2021-06-23 2022-06-22 THYMUS CELL COMPOSITIONS AND METHODS OF USE THEREOF Country Status (9) Country Link US ( 1 ) US20240117307A1 ( en ) EP ( 1 ) EP4359566A4 ( en ) JP ( 1 ) J
Bing Lim — NIH Funding & Grants | ConductScience Science Dex Institutions Investigators Medical Schools Methods Datasets Browse Grant Tools Shop Equipment Home / Investigators / Bing Lim BL Bing Lim Thymmune Therapeutics, Inc NIH Rank # 15048 Early Career NIH Funding · FY 2024 Total Funding $1M Fiscal year 2024 Grants Awarded 1 Active NIH grants National Rank #15,048 Among 57,894 PIs First NIH Award 2024 Year of first funding Funding & rank history NIH funding totals and national rank by fiscal year. Single fiscal year on record (FY 2024 ): $1M across 1 grant · National rank # 15048 . … n record (FY 2024 ): $1M across 1 grant · National rank # 15048 . Top grants by award amount Bing Lim 's NIH grant portfolio, ranked by award amount. 4R44AI170266-03 R44 Development of a stem-cell derived thymic cell therapy to treat patients with athymia Thymmune Therapeutics, Inc $1M award amount Affiliation Institutions that have administered grants for Bing Lim . Affiliated with Thymmune Therapeutics, Inc ( MA ). Career milestones Key NIH funding milestones over time … ( MA ). Career milestones Key NIH funding milestones over time. 2024 First NIH Award Thymmune Therapeutics, Inc 2024 $500K Cumulative Funding 2024 $1M Cumulative Funding Explore further Find collaborators for Bing Lim Search NIH-funded principal investigators by topic, department, or activity. Open Find Collaborators → Check S10 eligibility at Thymmune Therapeutics, Inc Review past S10 Shared Instrumentation Grant awards and equipment categories. Open S10 Eligibility Finder … Grant awards and equipment categories. Open S10 Eligibility Finder → Benchmark grant budgets Compare median NIH grant budgets across departments, mechanisms, and years. Open Grant Budget Benchmark → Rankings Medical Schools Departments All Institutions Investigators Explore Geographic Rankings Disciplines Overview Datasets About Methods Grant Planning Tools ConductScience ConductScience.com Lab Equipment Free Tools Data from NIH RePORTER . © 2026 ConductScience
Bing Lim — NIH Funding & Grants | ConductScience Science Dex Institutions Investigators Medical Schools Methods Datasets Browse Grant Tools Shop Equipment Home / Investigators / Bing Lim BL Bing Lim Thymmune Therapeutics, Inc NIH Rank # 15048 Early Career NIH Funding · FY 2024 Total Funding $1M Fiscal year 2024 Grants Awarded 1 Active NIH grants National Rank #15,048 Among 57,894 PIs First NIH Award 2024 Year of first funding Funding & rank history NIH funding totals and national rank by fiscal year. Single fiscal year on record (FY 2024 ): $1M across 1 grant · National rank # 15048 . … n record (FY 2024 ): $1M across 1 grant · National rank # 15048 . Top grants by award amount Bing Lim 's NIH grant portfolio, ranked by award amount. 4R44AI170266-03 R44 Development of a stem-cell derived thymic cell therapy to treat patients with athymia Thymmune Therapeutics, Inc $1M award amount Affiliation Institutions that have administered grants for Bing Lim . Affiliated with Thymmune Therapeutics, Inc ( MA ). Career milestones Key NIH funding milestones over time … ( MA ). Career milestones Key NIH funding milestones over time. 2024 First NIH Award Thymmune Therapeutics, Inc 2024 $500K Cumulative Funding 2024 $1M Cumulative Funding Explore further Find collaborators for Bing Lim Search NIH-funded principal investigators by topic, department, or activity. Open Find Collaborators → Check S10 eligibility at Thymmune Therapeutics, Inc Review past S10 Shared Instrumentation Grant awards and equipment categories. Open S10 Eligibility Finder … Grant awards and equipment categories. Open S10 Eligibility Finder → Benchmark grant budgets Compare median NIH grant budgets across departments, mechanisms, and years. Open Grant Budget Benchmark → Rankings Medical Schools Departments All Institutions Investigators Explore Geographic Rankings Disciplines Overview Datasets About Methods Grant Planning Tools ConductScience ConductScience.com Lab Equipment Free Tools Data from NIH RePORTER . © 2026 ConductScience
Bing Lim, MD, PhD - Chief Scientific Officer at Thymmune Therapeutics | The Org Platform Enrich Pricing Log in Sign up Thymmune Therapeutics Bing Lim, MD, PhD Unverified Bing Lim, MD, PhD Chief Scientific Officer Contact Bing Lim, MD, PhD has an extensive work experience spanning several prestigious institutions. Starting in 1988, they worked as an Associate Physician at Beth Israel Deaconess Medical Center until 2014. During this time, Dr. Lim identified novel hematopoietic-specific genes and played a key role in the research on ras-related small RhoGTPases. Bing also utilized embryonic ste
BioCentury - Tolerance Bio: Rejuvenating the thymus This Edition ARTICLE | Emerging Company Profile Tolerance Bio: Rejuvenating the thymus Starting with congenital athymia, former Provention Bio team aims to restore immune tolerance — with broader implications for lifespan extension By Danielle Golovin, Senior Biopharma Analyst January 15, 2026 9:01 PM UTC The Provention Bio team is back as Tolerance Bio for a second round of tackling immune tolerance, this time going upstream of T cells with therapies designed to preserve thymus function. While its first goal is to treat congenital athymia, t
Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multi … esources Blog Journalists RSS Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science - Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to further their research - News provided by Astellas Pharma Inc. Nov 03, 2021, 08:00 ET Share this article Share to X Share this article Share to X CAMBRIDGE, Mass. , Nov. 3, … and M13 Therapeutics as the winners of the Astellas-sponsored "Future Innovator Prize" at LabCentral. A Future Innovator Prize offers entrepreneurial scientists or emerging biotechnology startups one-year usage of LabCentral's state-of-the-art lab facility in Cambridge, Massachusetts , as well as access to Astellas' research and development (R&D) capabilities and business leaders. Thymmune and M13 were chosen for the strength of the innovation in their approach, the thera … across immunology. "We are grateful to be awarded an Astellas Future Innovator Prize," said Stan Wang , M.D., Ph.D., CEO of Thymmune Therapeutics. "Combining Astellas' cell therapy and immunology expertise with LabCentral's exciting incubator space allows us to push forward faster towards addressing immunologic disorders in a variety of therapeutic areas." M13 Therapeutics is a non-viral gene therapy platform working to overcome the limitations of the current gene therapy la … ia and other therapeutic areas such as oncology" "The Astellas Future Innovator Prize can give these emerging companies a leg up in their development process by giving access not only to our supportive environment, but also some of the brightest pharmaceutical minds in the industry at Astellas," said Johannes Fruehauf , LabCentral co-Founder and
Thymmune Therapeutics - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 08 May 2025 Thymmune Therapeutics Startups | Holding Company | 2019 | Massachusetts, United States | 10-50 | www.thymmune.com Startups | Holding Company | 2019 | Massachusetts, United States | 10-50 | www.thymmune.com Last update 08 May 2025 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Immune System Diseases Stem cell therapy Disease domain score A glimpse into the focused therapeutic … the same beneficiaries.” There are times when other HHS agencies might need to fund the same type of projects as ARPA-H, like when it’s necessary to confirm results, the GAO noted in the report. But, in other cases, doing so would be a waste of time and money, creating a need for oversight to ensure that ARPA-H research is “free of unnecessary duplication,” as the GAO put it. To do that, Congress established the ARPA-H Interagency Advisory Committee, a group of represe … report and as required, will respond with a written statement of actions by the deadline." As of February 2024, ARPA-H has put funds toward Every Cure’s machine learning and AI platform for drug repurposing, Thymmune Therapeutics’ stem-cell-based thymus rejuvenation, and 3D-printed organ development at Stanford University, among other projects. Editor's Note: ARPA-H returned FBR's request for comment on March 5. This article has been updated with the agency's respo … rtners. LPs are unlike general partners, which are involved in the venture fund they invest in. Instead, LPs are passive investors that make money from liquidity events, like an IPO. VCs typically have a minimum funding requirement for LPs to participate. Breakout used to have a $1 million minimum for new investors, which tend to be family offices, fund of funds, foundations and endowments, Moore explained. For its second fund, the firm lowered that minimum to $25,000 fo … access and information to a broader range of people. The firm closed its second fund in 2021 at $112.5 million. Diversity efforts don’t mean reinventing the wheel, either. a16z’s Agarwala underscored that the energy, momentum and foundation is already there, with diversity efforts more action-oriented than ever before. And it's important to ackno
Thymmune Therapeutics 0 Skip to Content Open Menu Close Menu Open Menu Close Menu Restoring Immune Function through Thymic Cell Engineering Developing Scalable Therapies for Aging and Disease Thymmune Therapeutics is a biotechnology company developing a machine learning-driven thymic cell engineering platform to restore normal immune function in aging and disease. The company’s cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale. The company is developing a pipeline of therapies to treat immunodeficiencies, transplant-related, and autoimmune disord … s to develop thymus-rejuvenating therapies. READ MORE BBJ: Thymmune gets ARPA-H grant to boost immune function in aging people READ MORE Thymmune Secures $7M in Seed Financing Thymmune secures $7 million in seed financing led by Pillar VC, with participation from NYBC Ventures and other investors. READ MORE Endpoints: Thymmune launches with backing from George Church, John Maraganore The Cambridge, MA-based biotech has raised $7 million in seed funding to push its thymic cell … MORE 2021 Thymmune Wins Astellas Golden Ticket Böhringer Ingelheim’s Innovation Prize LG Chem Life Sciences Golden Ticket Novo Nordisk Golden Ticket Pfizer Golden Ticket Winner Join us At Thymmune, we are passionate about developing best-in-class treatments to improve the lives of patients with immune-mediated diseases. We have created a collaborative and inclusive environment that thrives on intellectual curiosity and work in a fast-paced environment. We are dedicated to the … ch team member at Thymmune. To be considered for a position at Thymmune, please submit your CV and cover letter. Recruitment & Staffing Agencies: Thymmune Therapeutics does not accept unsolicited resumes from any source other than candidates. The submission of unsolicited resumes by recruitment or staffing agencies to Thymmune or its employees is strictly prohibited unless contacted directly by Thymmune’s internal Talent Acquisition team. Any resume submitted by an agency … une, and Thymmune will not owe any referral or other fees with respect thereto. SUBMIT View fullsize 215 First Street, Suite 401 Cambridge, MA 02142